Table 1 Baseline characteristics and MINORS scores of the enrolled studies
Study | Patients (n) | Male (n) | Follow-up (month) | TEE follow-up (month) | Device | CHADS2 | CHA2DS2-VASc | HAS-BLED | MINORS Score |
|---|---|---|---|---|---|---|---|---|---|
Swaans 2012 | 30 | 21 | 12 | 6 | Watchman | 2.5 | 3 | 2 | 12 |
Walker 2012 | 26 | 20 | 12 | 6 | Watchman | 1.9 | 2.6 | – | 12 |
Swaans 2013 | 10 | 5 | 6 | 1.5 | Watchman | 3 | 3.5 | 1.5 | 11 |
Alipour 2015 | 62 | 40 | 38 | 2 | Watchman | 2.5 | 3.0 | 2 | 12 |
Calvo 2015 | 35 | 25 | 13 | 3 | Watchman/Amplatzer | 2.01 | 3.1 | 3.1 | 12 |
Romanov 2015 | 45 | 28 | 24 | 6 | Watchman | – | 2.2 | 3.5 | 18a |
Phillips 2016 | 35 | 28 | 24 | 12 | Amplatzer/Watchman | – | 3 | 3 | 12 |
Fassini 2016 | 98 | 67 | 26.73 | 12 | Watchman | 1.5 | 2.6 | 1.9 | 10 |
Panikker 2016 | 20 | 13 | 12 | 9 | Watchman | – | 3.1 | 2.5 | 22a |
Pelissero 2017 | 21 | 14 | 14.93 | 14.93 | Watchman/Amplatzer | – | 2.8 | 3.2 | 12 |
Wintgens 2018 | 349 | 202 | 34.5 | 3 | Watchman | 2.0 | 3.0 | 3.0 | 10 |
Phillips 2018 | 139 | 76 | 1 | 1 | Watchman | 2.2 | 3.4 | 1.5 | 8 |
Du 2018 | 82 | 48 | 11.2 | 6 | Watchman | – | 4.4 | 3.5 | 12 |
Total | 952 | 587 | – | – | – | – | – | – | – |
Mean |  |  | 22.83 | 5.18 | – | – | – | – | – |